Globeflex Capital L P Increases Holdings in Jazz Pharmaceuticals PLC $JAZZ

Globeflex Capital L P boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 130.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 10,594 shares of the specialty pharmaceutical company’s stock after buying an additional 6,003 shares during the period. Globeflex Capital L P’s holdings in Jazz Pharmaceuticals were worth $2,003,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Ruffer LLP purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $2,425,000. Allianz Asset Management GmbH grew its stake in Jazz Pharmaceuticals by 68.2% in the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after acquiring an additional 242,892 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $1,700,000. Swedbank AB increased its holdings in Jazz Pharmaceuticals by 2.7% during the 4th quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock valued at $187,506,000 after acquiring an additional 28,882 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in Jazz Pharmaceuticals by 274.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 8,583 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 6,292 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $250.41 on Thursday. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $255.20. The company’s 50 day simple moving average is $236.40 and its 200 day simple moving average is $202.31. The company has a market capitalization of $15.73 billion, a price-to-earnings ratio of -12,514.24, a PEG ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares of the company’s stock, valued at $88,176,020.54. The trade was a 1.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 13,098 shares of company stock valued at $3,131,906 in the last quarter. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on JAZZ. Leerink Partners upped their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Royal Bank Of Canada raised their price objective on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Morgan Stanley reiterated an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $188.00 to $307.00 in a report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $259.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.